

Supplementary Table 2. Baseline demographics of enrolled patients and patients who underwent EVT before END

Variable	Enrolled patients (n=94)	Excluded patients: EVT before END (n=14)	P
Age (yr)	66.9±13.0	67.5±15.0	0.887
Men	49 (52.1)	10 (71.4)	0.176
Baseline NIHSS	2.12±1.63	3.93±1.49	<0.001
Onset-to-door time (hr)	3.23 (1.45–9.33)	2.93 (0.65–5.00)	0.141
Pre-stroke mRS			1.000
0	80 (85.1)	12 (85.7)	
1	14 (14.9)	2 (14.3)	
Stroke mechanism			0.705
LAA	42 (44.7)	5 (35.7)	
CE	36 (38.3)	7 (50.0)	
Other determined	0 (0)	0 (0)	
Undetermined	16 (17.0)	2 (14.3)	
Site of occlusion			0.020
Intracranial ICA	7 (7.4)	0 (0.0)	
Tandem	6 (6.4)	3 (21.4)	
MCA M1	44 (46.8)	10 (71.4)	
MCA M2 trunk	37 (39.4)	1 (7.1)	
Hypertension	63 (67.0)	9 (64.3)	1.000
Diabetes mellitus	25 (26.6)	3 (21.4)	1.000
Hyperlipidemia	37 (39.4)	4 (28.6)	0.438
Atrial fibrillation	26 (27.7)	5 (35.7)	0.538
MI or angina	9 (9.6)	1 (7.1)	1.000
Prior stroke	11 (11.7)	2 (14.3)	0.675
Smoking	19 (20.2)	4 (28.6)	0.491
SBP (mm Hg)	157.2±31.1	160.0±35.4	0.869
DBP (mm Hg)	86.57±17.0	88.9±12.4	0.699
Leukocyte count (n/µL)	8,075.1±2,324.8	8,581.4±3,376.1	0.883
Hemoglobin (g/dL)	13.7±1.5	12.9±3.5	0.998
Hematocrit (%)	39.9±4.1	39.5±4.1	0.855
Platelet count (n/µL)	245,053±74,857	209,143±58,010	0.075
ESR (mm/hr)	10.0 (5.0–19.0)	5.0 (2.0–12.5)	0.036
CRP (mg/dL)	0.25 (0.08–0.34)	0.16 (0.09–0.30)	0.922
Fibrinogen (mg/dL)	287.2±82.7	268.3±66.8	0.539
Baseline glucose (mg/dL)	143.8±51.4	149.0±75.0	0.991
Type of recanalization therapy			
IV tPA	28 (29.8)	4 (28.6)	1.000
Rescue EVT	23 (24.5)	14 (100.0)	<0.001

Values are presented as mean±standard deviation, number (%), or median (interquartile range).

EVT, endovascular therapy; END, early neurological deterioration; NIHSS, National Institutes of Health Stroke Scale; mRS, modified Rankin Scale; LAA, large artery atherosclerosis; CE, cardioembolism; ICA, internal carotid artery; MCA, middle cerebral artery; MI, myocardial infarction; SBP, systolic blood pressure; DBP, diastolic blood pressure; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IV tPA, intravenous tissue-type plasminogen activator.